Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
VMF
DRUG PRODUCT COMPOSITIONS
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers


| Molecular Weight | 539.6 g/mol |
|---|---|
| Molecular Formula | C31H33N5O4 |
| XLogP3 | 3.3 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 7 |
| Rotatable Bond Count | 8 |
| Exact Mass | 539.25325455 g/mol |
| Monoisotopic Mass | 539.25325455 g/mol |
| Topological Polar Surface Area | 94.2 A^2 |
| Heavy Atom Count | 40 |
| Formal Charge | 0 |
| Complexity | 947 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 1 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
| 1 of 2 | |
|---|---|
| Drug Name | Ofev |
| Drug Label | OFEV capsules contain nintedanib, a kinase inhibitor [see Mechanism of Action (12.1)]. Nintedanib is presented as the ethanesulfonate salt (esylate), with the chemical name 1H-Indole-6-carboxylic acid, 2,3-dihydro-3-[[[4-[methyl[(4-methyl-1-piperazin... |
| Active Ingredient | Nintedanib |
| Dosage Form | Capsule |
| Route | Oral |
| Strength | 150mg; 100mg |
| Market Status | Prescription |
| Company | Boehringer Ingelheim |
| 2 of 2 | |
|---|---|
| Drug Name | Ofev |
| Drug Label | OFEV capsules contain nintedanib, a kinase inhibitor [see Mechanism of Action (12.1)]. Nintedanib is presented as the ethanesulfonate salt (esylate), with the chemical name 1H-Indole-6-carboxylic acid, 2,3-dihydro-3-[[[4-[methyl[(4-methyl-1-piperazin... |
| Active Ingredient | Nintedanib |
| Dosage Form | Capsule |
| Route | Oral |
| Strength | 150mg; 100mg |
| Market Status | Prescription |
| Company | Boehringer Ingelheim |
Date of Issue : 2023-11-28
Valid Till : 2026-11-28
Written Confirmation Number : WC-0310
Address of the Firm : Plot No. Z-103/l, Dahej SEZ, Phase II, Dahej, Dist-Bharuch, Gujarat, India

Date of Issue : 2025-12-03
Valid Till : 2028-04-14
Written Confirmation Number : WC-0340
Address of the Firm : R.S No: 578, Near Effluent Channel, at & Post: Luna, Taluka: Padra, District: Va...

Date of Issue : 2022-09-30
Valid Till : 2025-04-14
Written Confirmation Number : WC-340n
Address of the Firm : RS No: 578, Near Effluent Channel, at & Post: Luna, Taluka: Padra, District: Vad...

Date of Issue : 2025-08-26
Valid Till : 2028-08-08
Written Confirmation Number : WC-0113
Address of the Firm : Old Madras Road, Virgo Nagar Post, Bengaluru - 560049, Karnataka, India

Date of Issue : 2025-09-03
Valid Till : 2028-08-08
Written Confirmation Number : WC-0041
Address of the Firm : Unit-I, Sy. No. 10, I.D.A, Gaddapotharam (V), Jinnaram (M), Sangareddy District,...

Date of Issue : 2025-09-19
Valid Till : 2028-05-05
Written Confirmation Number : WC-0349
Address of the Firm : Unit-II, Sy. Nos. 50, 53, 53/A, 54 & 54/A,Kardanur (Village), Patancheru (Mandal...

Date of Issue : 2025-09-19
Valid Till : 2028-05-05
Written Confirmation Number : WC-0349
Address of the Firm : Unit-II, Sy. Nos. 50, 53, 53/A, 54 & 54/A,Kardanur (Village), Patancheru (Mandal...

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]NDC Package Code : 76361-0003
Start Marketing Date : 2024-04-01
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT

NDC Package Code : 51869-0040
Start Marketing Date : 2014-10-14
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (25kg/25kg)
Marketing Category : BULK INGREDIENT

NDC Package Code : 65727-104
Start Marketing Date : 2025-03-26
End Marketing Date : 2027-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT

NDC Package Code : 12714-133
Start Marketing Date : 2014-10-15
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (20kg/20kg)
Marketing Category : BULK INGREDIENT

NDC Package Code : 48943-0037
Start Marketing Date : 2025-04-02
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT

NDC Package Code : 66499-0062
Start Marketing Date : 2018-04-26
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT

NDC Package Code : 66529-0015
Start Marketing Date : 2019-12-20
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT

NDC Package Code : 54893-0059
Start Marketing Date : 2017-03-27
End Marketing Date : 2027-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT

NDC Package Code : 17337-0093
Start Marketing Date : 2020-06-15
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT

NDC Package Code : 63592-7200
Start Marketing Date : 2016-07-29
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (100kg/100kg)
Marketing Category : BULK INGREDIENT

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Global Sales Information
Company : Boehringer Ing.
Nintedanib Esylate
Drug Cost (USD) : 1,837,061,150
Year : 2023
Prescribers : 20444
Prescriptions : 140681

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company : Boehringer Ing.
Nintedanib Esylate
Drug Cost (USD) : 1,762,963,783
Year : 2022
Prescribers : 20686
Prescriptions : 143756

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company : Boehringer Ing.
Nintedanib Esylate
Drug Cost (USD) : 1,495,198,249
Year : 2021
Prescribers : 19476
Prescriptions : 129070

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company : Boehringer Ing.
Nintedanib Esylate
Drug Cost (USD) : 1,157,563,828
Year : 2020
Prescribers : 15902
Prescriptions : 105327

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company : Boehringer Ing.
Nintedanib Esylate
Drug Cost (USD) : 789,557,042
Year : 2019
Prescribers : 11971
Prescriptions : 77644

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company : Boehringer Ing.
Nintedanib Esylate
Drug Cost (USD) : 618,635,442
Year : 2018
Prescribers : 9834
Prescriptions : 66472

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company : Boehringer Ing.
Nintedanib Esylate
Drug Cost (USD) : 494,127,312
Year : 2017
Prescribers : 8645
Prescriptions : 56161

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company : Boehringer Ing.
Nintedanib Esylate
Drug Cost (USD) : 371,895,203
Year : 2016
Prescribers : 7231
Prescriptions : 43849

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Dosage Form : Nintedanib 100Mg 60 Units Oral U...
Dosage Strength : 1x60 soft cps 100 mg
Price Per Pack (Euro) : 4,050.34
Published in :
Country : Italy
RX/OTC/DISCN : Class H

Dosage Form : Nintedanib 150Mg 60 Units Oral U...
Dosage Strength : 1x60 soft cps 150 mg
Price Per Pack (Euro) : 4,050.34
Published in :
Country : Italy
RX/OTC/DISCN : Class H

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
16
PharmaCompass offers a list of Nintedanib Esylate API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Nintedanib Esylate manufacturer or Nintedanib Esylate supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Nintedanib Esylate manufacturer or Nintedanib Esylate supplier.
A Vargatef manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Vargatef, including repackagers and relabelers. The FDA regulates Vargatef manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Vargatef API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Vargatef manufacturers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PhamaCompass.
A Vargatef supplier is an individual or a company that provides Vargatef active pharmaceutical ingredient (API) or Vargatef finished formulations upon request. The Vargatef suppliers may include Vargatef API manufacturers, exporters, distributors and traders.
click here to find a list of Vargatef suppliers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PharmaCompass.
A Vargatef DMF (Drug Master File) is a document detailing the whole manufacturing process of Vargatef active pharmaceutical ingredient (API) in detail. Different forms of Vargatef DMFs exist exist since differing nations have different regulations, such as Vargatef USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Vargatef DMF submitted to regulatory agencies in the US is known as a USDMF. Vargatef USDMF includes data on Vargatef's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Vargatef USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Vargatef suppliers with USDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Vargatef Drug Master File in Korea (Vargatef KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Vargatef. The MFDS reviews the Vargatef KDMF as part of the drug registration process and uses the information provided in the Vargatef KDMF to evaluate the safety and efficacy of the drug.
After submitting a Vargatef KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Vargatef API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Vargatef suppliers with KDMF on PharmaCompass.
A Vargatef written confirmation (Vargatef WC) is an official document issued by a regulatory agency to a Vargatef manufacturer, verifying that the manufacturing facility of a Vargatef active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Vargatef APIs or Vargatef finished pharmaceutical products to another nation, regulatory agencies frequently require a Vargatef WC (written confirmation) as part of the regulatory process.
click here to find a list of Vargatef suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Vargatef as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Vargatef API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Vargatef as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Vargatef and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Vargatef NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Vargatef suppliers with NDC on PharmaCompass.
Vargatef Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Vargatef GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Vargatef GMP manufacturer or Vargatef GMP API supplier for your needs.
A Vargatef CoA (Certificate of Analysis) is a formal document that attests to Vargatef's compliance with Vargatef specifications and serves as a tool for batch-level quality control.
Vargatef CoA mostly includes findings from lab analyses of a specific batch. For each Vargatef CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Vargatef may be tested according to a variety of international standards, such as European Pharmacopoeia (Vargatef EP), Vargatef JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Vargatef USP).